Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

NCT03212742 is registered in ClinicalTrials.gov with Centre Francois Baclesse as lead sponsor.

NCT NCT03212742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03212742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
Lead sponsor
Centre Francois Baclesse
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 4, 2017
Completion date
December 31, 2026
Enrollment
91 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

malignant gliomas, parp inhibitor, radiotherapy